Compare CRIS & PIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRIS | PIII |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 33.8M |
| IPO Year | 2000 | 2021 |
| Metric | CRIS | PIII |
|---|---|---|
| Price | $1.83 | $10.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $17.00 | $9.00 |
| AVG Volume (30 Days) | ★ 241.6K | 32.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $9,898,000.00 | ★ $1,459,080,000.00 |
| Revenue This Year | $27.10 | $7.67 |
| Revenue Next Year | $67.74 | $2.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.18 | $1.52 |
| 52 Week High | $6.74 | $16.89 |
| Indicator | CRIS | PIII |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 48.58 |
| Support Level | $0.66 | $9.71 |
| Resistance Level | $5.55 | $11.55 |
| Average True Range (ATR) | 0.54 | 1.09 |
| MACD | -0.46 | 0.03 |
| Stochastic Oscillator | 8.13 | 22.70 |
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.